Pharmacokinetic evaluation of piperacillin-tazobactam

Bibliography

• Projan SJ. Francis tally and the discovery and development of tigecycline: a personal reminiscence. Clin Infect Dis 2010;50(S1):S24-5
   PubMedGoogle Scholar
• Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated Pneumonia. Am J Respir Crit Care Med 2005;171(4):388-416
   PubMed Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A, Infectious Diseases Society of America/American Thoracic Society Consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(S2):S27-72
   PubMedGoogle Scholar
• Mermel LA, Allon M, Bouza E, Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;49(1):1-45
   PubMed Web of Science ®Google Scholar
• Lipsky BA, Berendt AR, Deery HG, Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004;39(7):885-10
   PubMed Web of Science ®Google Scholar
• Stevens DL, Bisno AL, Chambers HF, Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41(10):1373-406
   PubMed Web of Science ®Google Scholar
• Solomkin JS, Mazuski JE, Bradley JS, Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010;50(2):133-64
   PubMed Web of Science ®Google Scholar
• Hughes WT, Armstrong D, Bodey GP, 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34(6):730-51
   PubMed Web of Science ®Google Scholar
• Dellinger RP, Levy MM, Carlet JM, Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36(1):296-327
   PubMed Web of Science ®Google Scholar
• Boucher HW, Talbot GH, Bradley JS, Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48(1):1-12
   PubMed Web of Science ®Google Scholar
• Culver SM, Martens MG. Piperacillin/tazobactam (ZOSYN). Infect Dis Obstet Gynecol 1996;4(5):258-62
   PubMedGoogle Scholar
• Wyeth Pharmceticals, Inc. Zosyn product information; 2009
   Google Scholar
• Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 2010;23(1):160-201
   PubMed Web of Science ®Google Scholar
• Sorgel F, Kinzig M. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J Antimicrob Chemother 1993;31(Suppl_A):39-60
   PubMedGoogle Scholar
• Essack SY. The development of beta-lactam antibiotics in response to the evolution of beta-lactamases. Pharm Res 2001;18(10):1391-9
   PubMed Web of Science ®Google Scholar
• Livermore DM. Determinants of the activity of beta-lactamase inhibitor combinations. J Antimicrob Chemother 1993;31(Suppl A):9-21
   PubMedGoogle Scholar
• Papp-Wallace KM, Bethel CR, Distler AM, Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase. Antimicrob Agents Chemother 2010;54(2):890-7
   PubMed Web of Science ®Google Scholar
• Gavin PJ, Suseno MT, Thomson RB Jr, Clinical correlation of the CLSI susceptibility breakpoint for piperacillin-tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella Species. Antimicrob Agents Chemother 2006;50(6):2244-7
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Navarro MD, Romero L, Bacteremia due to extendeded spectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006;43(11):1407-14
   PubMed Web of Science ®Google Scholar
• Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008;8(3):159-66
   PubMed Web of Science ®Google Scholar
• Aronoff GR, Sloan RS, Brier ME, The effect of piperacillin dose on elimination kinetics in renal impairment. Eur J Clin Pharmacol 1983;24(4):543-7
   PubMed Web of Science ®Google Scholar
• Bergan T, Williams JD. Dose dependence of piperacillin pharmacokinetics. Chemotherapy 1982;28(3):153-9
   PubMed Web of Science ®Google Scholar
• Kim M-K, Xuan D, Quintiliani R, Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam. J Antimicrob Chemother 2001;48(2):259-67
   PubMed Web of Science ®Google Scholar
• Vinks AA, den Hollander JG, Overbeek SE, Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis. Antimicrob Agents Chemother 2003;47(2):541-7
   PubMed Web of Science ®Google Scholar
• Tjandramaga TB, Mullie A, Verbesselt R, Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. Antimicrob Agents Chemother 1978;14(6):829-37
   PubMed Web of Science ®Google Scholar
• Roberts JA, Roberts MS, Robertson TA, Piperacillin penetration into tissue of critically ill patients with sepsis-Bolus versus continuous administration? Crit Care Med 2009;37(3):926-33
   PubMed Web of Science ®Google Scholar
• Roberts JA, Kirkpatrick CM, Roberts MS, First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 2010;35(2):156-63
   PubMed Web of Science ®Google Scholar
• Li C, Kuti JL, Nightingale CH, Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother 2005;56(2):388-95
   PubMed Web of Science ®Google Scholar
• Sorgel F, Kinzig M. Pharmacokinetic characteristics of piperacillin/tazobactam. Intensive Care Med 1994;20(Suppl 3):14-20
   Google Scholar
• Kinzig M, Sorgel F, Brismar B, Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery. Antimicrob Agents Chemother 1992;36(9):1997-2004
   PubMed Web of Science ®Google Scholar
• Incavo SJ, Ronchetti PJ, Choi JH, Penetration of piperacillin-tazobactam into cancellous and cortical bone tissues. Antimicrob Agents Chemother 1994;38(4):905-7
   PubMed Web of Science ®Google Scholar
• Nau R, Kinzig-Schippers M, Sorgel F, Kinetics of piperacillin and tazobactam in ventricular cerebrospinal fluid of hydrocephalic patients. Antimicrob Agents Chemother 1997;41(5):987-91
   PubMed Web of Science ®Google Scholar
• Jones RN, Stilwell MG, Rhomberg PR, Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007). Diagn Microbiol Infect Dis 2009;65(3):331-4
   PubMed Web of Science ®Google Scholar
• Fujimura T, Anan N, Sugimori G, Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents. Int J Antimicrob Agents 2009;34(6):523-8
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Turnidge JD, Bell J, The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008). J Infect 2010;60(6):440-51
   PubMed Web of Science ®Google Scholar
• Wang H, Chen M, Ni Y, Antimicrobial resistance among clinical isolates from the Chinese Meropenem Surveillance Study (CMSS), 2003-2008. Int J Antimicrob Agents 2010;35(3):227-34
   PubMed Web of Science ®Google Scholar
• Garrison MW, Mutters R, Dowzicky MJ. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: Tigecycline Evaluation and Surveillance Trial 2004 to 2007. Diagn Microbiol Infect Dis 2009;65(3):288-99
   PubMed Web of Science ®Google Scholar
• Turner PJ. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates. Diagn Microbiol Infect Dis 2009;63(2):217-22
   PubMed Web of Science ®Google Scholar
• Pillar CM, Torres MK, Brown NP, In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by Gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob Agents Chemother 2008;52(12):4388-99
   PubMed Web of Science ®Google Scholar
• Rossi F, Garcia P, Ronzon B, Rates of antimicrobial resistance in Latin America (2004-2007) and in vitro activity of the glycylcycline tigecycline and of other antibiotics. Braz J Infect Dis 2008;12(5):405-15
   PubMed Web of Science ®Google Scholar
• Higgins PG, Wisplinghoff H, Stefanik D, In Vitro Activities of the beta-lactamase inhibitors Clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii Strains. Antimicrob Agents Chemother 2004;48(5):1586-92
   PubMed Web of Science ®Google Scholar
• The Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twentieth International Supplement; 2010
   Google Scholar
• The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters Version 1.0 December 2009
   Google Scholar
• Wise R, Logan M, Cooper M, Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob Agents Chemother 1991;35(6):1081-4
   PubMed Web of Science ®Google Scholar
• Westphal JF, Brogard JM, Caro-Sampara F, Assessment of biliary excretion of piperacillin-tazobactam in humans. Antimicrob Agents Chemother 1997;41(8):1636-40
   PubMed Web of Science ®Google Scholar
• Aronoff GR, Sloan RS, Brier ME, The effect of piperacillin dose on elimination kinetics in renal impairment. Eur J Clin Pharmacol 1983;24(4):543-7
   PubMed Web of Science ®Google Scholar
• Brogard JM, Jehl F, Blickle JF, Biliary pharmacokinetic profile of piperacillin: experimental data and evaluation in man. Int J Clin Pharmacol Ther Toxicol 1990;28(11):462-70
   PubMedGoogle Scholar
• Roberts J, Ulldemolins M, Roberts M, Therapetuic drug monitoring of Beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 2010; In press
   Google Scholar
• Perry CM, Markham A. Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections. Drugs 1999;57(5):805-43
   PubMed Web of Science ®Google Scholar
• Legat FJ, Krause R, Zenahlik P, Penetration of piperacillin and tazobactam into inflamed soft tissue of patients with diabetic foot infection. Antimicrob Agents Chemother 2005;49(10):4368-71
   PubMed Web of Science ®Google Scholar
• Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009;37(3):840-51
   PubMed Web of Science ®Google Scholar
• Bulitta JB, Duffull SB, Kinzig-Schippers M, Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 2007;51(7):2497-507
   PubMed Web of Science ®Google Scholar
• Landersdorfer C. Modern pharmacokinetic-pharmacodynamic techniques to study physiological mechanisms of pharmacokinetic drug-drug interactions and disposition of antibiotics and to assess clinical relevance Universitat Wurzburg, Fakultat fur Chemie und Pharmazie. Institut fur Pharmazie und Lebensmittelchemie, 2006
   Google Scholar
• Florian T, Peter D, Alfred M, Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by in vivo microdialysis. Br J Clin Pharmacol 2003;55(6):620-4
   PubMed Web of Science ®Google Scholar
• Boselli E, Breilh D, Cannesson M, Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 2004;30(5):976-9
   PubMed Web of Science ®Google Scholar
• Boselli E, Breilh D, Rimmele T, Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia. Crit Care Med 2008;36(5):1500-6
   PubMed Web of Science ®Google Scholar
• Blondiaux N, Wallet F, Favory R, Daily serum piperacillin monitoring is advisable in critically ill patients. Int J Antimicrob Agents 2010;35(5):500-3
   PubMed Web of Science ®Google Scholar
• Joukhadar C, Frossard M, Mayer BX, Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 2001;29(2):385-91
   PubMed Web of Science ®Google Scholar
• van der Werf TS, Mulder PO, Zijlstra JG, Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH). Intensive Care Med 1997;23(8):873-7
   PubMed Web of Science ®Google Scholar
• Capellier G, Cornette C, Boillot A, Removal of piperacillin in critically ill patients undergoing continuous venovenous hemofiltration. Crit Care Med 1998;26(1):88-91
   PubMed Web of Science ®Google Scholar
• Valtonen M, Tiula E, Takkunen O, Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother 2001;48(6):881-5
   PubMed Web of Science ®Google Scholar
• Arzuaga A, Isla A, Gascon AR, Elimination of piperacillin and tazobactam by renal replacement therapies with AN69 and polysulfone hemofilters: evaluation of the sieving coefficient. Blood Purif 2006;24(4):347-54
   PubMed Web of Science ®Google Scholar
• Arzuaga A, Maynar J, Gascon AR, Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration. J Clin Pharmacol 2005;45(2):168-76
   PubMed Web of Science ®Google Scholar
• Bourget P, Lesne-Hulin A, Le Reveille R, Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection. Antimicrob Agents Chemother 1996;40(1):139-45
   PubMed Web of Science ®Google Scholar
• Newman D, Scheetz MH, Adeyemi OA, Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual. Ann Pharmacother 2007;41(10):1734-9
   PubMed Web of Science ®Google Scholar
• Bourget P, Sertin A, Lesne-Hulin A, Influence of pregnancy on the pharmacokinetic behaviour and the trans-placental transfer of the piperacillin-tazobactam combination. Eur J Obstet Gynecol Reprod Biol 1998;76(1):21-7
   PubMed Web of Science ®Google Scholar
• Reed MD, Goldfarb J, Yamashita TS, Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children. Antimicrob Agents Chemother 1994;38(12):2817-26
   PubMed Web of Science ®Google Scholar
• Burgess DS, Waldrep T. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing. Clin Ther 2002;24(7):1090-104
   PubMed Web of Science ®Google Scholar
• Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26(1):1-10
   PubMed Web of Science ®Google Scholar
• Lodise TP, Lomaestro BM, Drusano GL. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006;26(9):1320-32
   PubMed Web of Science ®Google Scholar
• DeRyke CA, Kuti JL, Nicolau DP. Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. Diagn Microbiol Infect Dis 2007;58(3):337-44
   PubMed Web of Science ®Google Scholar
• Gin A, Dilay L, Karlowsky JA, Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination. Expert Rev Anti Infect Ther 2007;5(3):365-83
   PubMed Web of Science ®Google Scholar
• Rea-Neto A, Niederman M, Margareth Lobo S, Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin 2008;24(7):2113-26
   PubMed Web of Science ®Google Scholar
• Schmitt D, Leitner E, Welte T, Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia – a double Blind Prospective Multicentre Study. Infection 2006;34(3):127-34
   PubMed Web of Science ®Google Scholar
• Namias N, Solomkin JS, Jensen EH, Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults. Surg Infect 2007;8(1):15-28
   PubMedGoogle Scholar
• Dela Pena AS, Asperger W, Kockerling F, Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention. J Gastrointest Surg 2006;10(4):567-74
   PubMed Web of Science ®Google Scholar
• Erasmo AA, Crisostomo AC, Yan LN, Randomized comparison of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of patients with intra-abdominal infection. Asian J Surg 2004;27(3):1015-9584
   Google Scholar
• Solomkin JS, Yellin AE, Rotstein OD, Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a Double-Blind, Randomized Comparative Phase III Trial. Ann Surg 2003;237(2):235-45
   PubMed Web of Science ®Google Scholar
• Bow EJ, Rotstein C, Noskin GA, A Randomized, Open-Label, Multicenter Comparative Study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis 2006;43(4):447-59
   PubMed Web of Science ®Google Scholar
• Harter C, Schulze B, Goldschmidt H, Piperacillin//tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial. Bone Marrow Transplant 2006;37(4):373-9
   PubMed Web of Science ®Google Scholar
• Gernot R, Oliver AC, Michael S, Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial. Br J Haematol 2005;130(2):265-70
   PubMed Web of Science ®Google Scholar
• Del Favero A, Menichetti F, Martino P, A Multicenter, Double-Blind, Placebo-Controlled Trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 2001;33(8):1295-301
   PubMed Web of Science ®Google Scholar
• Lipsky BA, Armstrong DG, Citron DM, Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet 2005;366(9498):1695-703
   PubMed Web of Science ®Google Scholar
• Saltoglu N, Dalkiran A, Tetiker T, Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital. Clin Microbiol Infect 2009. [Epub ahead of print]. Doi: 10.1111/j.1469-0691.2009.03067.x
   Google Scholar
• Gesser RM, McCarroll KA, Woods GL. Evaluation of outpatient treatment with ertapenem in a double blind controlled clinical trial of complicated skin/skin structure infections. J Infection 2004;48(1):32-8
   PubMed Web of Science ®Google Scholar
• Graham DR, Lucasti C, Malafaia O, Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a Prospective, Randomized, Double-Blind Multicenter Study. Clin Infect Dis 2002;34(11):1460-8
   PubMed Web of Science ®Google Scholar
• Fau RS, Higareda I, Angel-Muller E, Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study. Infect Dis Obstet Gynecol 2003;11(1):1064-7449
   Google Scholar
• Shea KM, Cheatham SC, Wack MF, Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients. Int J Antimicrob Agents 2009;34(5):429-33
   PubMed Web of Science ®Google Scholar
• Kim M-K, Capitano B, Mattoes HM, Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam. Pharmacotherapy 2002;22(5):569-77
   PubMed Web of Science ®Google Scholar
• Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol Infect 2005;11(12):974-84
   PubMed Web of Science ®Google Scholar
• Sader HS, Jones RN. Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Int J Antimicrob Agents 2005;25(2):95-109
   PubMed Web of Science ®Google Scholar
• Zhanel GG, DeCorby M, Nichol KA, Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006. Diagn Microbiol Infect Dis 2008;62(1):67-80
   PubMed Web of Science ®Google Scholar
• Rhomberg PR, Jones RN. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). Diagn Microbiol Infect Dis 2007;57(2):207-15
   PubMed Web of Science ®Google Scholar
• Nagy E, Dowzicky MJ. In vitro activity of tigecycline and comparators against a European compilation of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (TEST). Scand J Infect Dis 2010;42(1):33-8
   PubMed Web of Science ®Google Scholar
• Elisabeth N, Edit U, Carl Erik N. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe; twenty years' experience. Clin Microbiol Infect 2010: In press
   Google Scholar
• Wybo I, Pierard D, Verschraegen I, Third Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria. J Antimicrob Chemother 2007;59(1):132-9
   PubMed Web of Science ®Google Scholar
• Johnson CA, Halstenson CE, Kelloway JS, Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Clin Pharmacol Ther 1992;51(1):32-41
   PubMed Web of Science ®Google Scholar